GEO DataSet Links for PMC (Select 4059833) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from PMC

Items: 2

Select item 2000330121.

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(Submitter supplied) Knowledge of essential oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells bearing an oncogenic mutation while sparing normal cells. Lenalidomide is emerging as an active agent in diffuse large B cell lymphoma (DLBCL), especially for the activated B cell-like (ABC) subtype, but the mechanism of its action is unknown. Here we show that lenalidomide kills ABC DLBCL cells by augmenting the production of interferon 3/4, which these cells are predisposed to produce by their oncogenic MYD88 mutations. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL4133
8 Samples

Download data: TXT

Series

Accession:: GSE33012

ID:: 200033012

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000324562.

Co-addiction to IRF4 and SPIB in ABC-DLBCL

(Submitter supplied) RNA interference screens identified the transcription factor IRF4 as essential for the survival of the activated B-cell-like subtype of diffuse large B-cell lymphoma (ABC-DLBCL). Analysis of IRF4 genomic targets in ABC-DLBCL and Multiple Myeloma (MM) revealed that IRF4 regulates distinct networks in these cancers. IRF4 peaks in ABC-DLBCL, but not MM, were enriched for a composite ETS-IRF DNA motif that can be bound by heterodimers of IRF4 and the ETS-family transcription factor SPIB, whose expression is also essential for ABC-DLBCL survival. more...